Gentiopicroside inhibits the progression of gastric cancer through modulating EGFR/PI3K/AKT signaling pathway
ConclusionsOur investigation demonstrated for the first time that GPS could inhibit GC malignant progression by targeting the EGFR/PI3K/AKT signaling pathway. This study indicated that GPS may be serve as a safe anti-tumor drug for further treatment of GC.
Source: European Journal of Medical Research - Category: Research Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Drugs & Pharmacology | Gastric (Stomach) Cancer | Gastroenterology | Heart | Liver | Research | Study | Toxicology | Urology & Nephrology